Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects

Biomedicine and Pharmacotherapy

Volumn 64, Issue 2, 2010, Pages 88-92

  Shen, Hua ^a   Yuan, Yuan ^a   Sun, Jing ^a   Gao, Wen ^a   Shu, Yong Qian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

EGFR ER pathway; Gefitinib; NSCLC; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR BETA; GEFITINIB; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 77349084154     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.06.010     Document Type: Article

References (20)

1. Tonon G., Wong K.K., Maulik G., Brennan C., Feng B., Zhang Y., et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005, 102:9625-9630.
2. Patel J.D., Bach P.B., Kris M.G. Lung cancer in US women. A contemporary epidemic. JAMA 2004, 291:1763-1768.
3. Stabile L.P., Davis A.L., Gubish C.T., et al. Human nonsmall cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 2002, 62:141-150.
4. Hershberger P.A., Vasquez A.C., Siegfried J.M., Nichols M.D. Lung cancer cells express estrogen receptor (ER) and coactivators and undergo changes in gene expression in response to ER ligands. Proc AACR 2004, 45:289.
5. Miettinen P.J., Berger J.E., Meeses J., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
6. Sibilia M., Wagner E.F. Strain dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234-238.
7. Threadgill D.W., Dlugosz A.A., Hansen L.A., et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995, 269:230-234.
8. Okubo S., Kurebayashi J., Otsuki T., et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004, 90:236-244.
9. Patrone C., Cassel T.N., Pettersson K., et al. Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 2003, 23:8542-8552.
10. Omoto Y., Kobayashi Y., Nishida K., et al. Expression,function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 2001, 285:340-347.
11. Hamilton A., Piccart M. The third-generation nonsteroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999, 10:377-384.
12. Giudici D., Ornati G., Briatico G., et al. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988, 30:391-394.
13. Hoang T., Traynor A.M., Schiller J.H. Novel therapies for lung cancer. Surg Oncol 2002, 11:229-241.
14. Foon K.A., Yang X.D., Weiner L.M., et al. Preclinical and clinical evaluations of ABX-EGF, a fully human antiepidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004, 58:984-990.
15. Arteaga C.L., Johnson D.H. Tyrosine kinase inhibitors: ZD1839 (Iressa). Curr Opin Oncol 2001, 13:491-498.
16. Gonzalez G., Crombet T., Catala M., et al. A novel cancer vaccine composed of human recombinant EGF linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998, 9:1-5.
17. Rowinsky EK. Targeting signal transduction: the erbB receptor family as a target for therapeutic development against cancer. Horizons in cancer therapeutics: from bench to bedside. 2001. p. 3-36.
18. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumorspecific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000, 97:7503-7508.
19. Lee A.V., Cui X., Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulinlike growth factor signaling in breast cancer. Clin Cancer Res 2001, 7:4429-4435.
20. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003, 17:309-317.